Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) CLIA Kit

845€ (96 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) CLIA Kit
category
CLIA Kits
provider
Abbexa
reference
abx495289
tested applications
CLIA
Description
Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Chemiluminescent Immunoassay (CLIA) Kit is a Sandwich Chemiluminescent Immunoassay (CLIA) Kit for use with Serum, plasma, tissue homogenates and other biological fluids.
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | CLIA Kits |
Immunogen Target | Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) |
Reactivity | Human |
Detection Method | Chemiluminescent |
Assay Data | Quantitative |
Assay Type | Sandwich |
Test Range | 78.12 pg/ml - 5000 pg/ml |
Sensitivity | < 27 pg/ml |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Size 1 | 96 tests |
Size 2 | 5 × 96 tests |
Size 3 | 10 × 96 tests |
Form | Lyophilized |
Tested Applications | CLIA |
Sample Type | Serum, plasma, tissue homogenates and other biological fluids. |
Availability | Shipped within 5-20 working days. |
Storage | Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual. |
Dry Ice | No |
Alias | BCAR1, CAS, CAS1, CASS1, CRKAS, P130Cas, Cas family scaffolding protein, Cas family scaffold protein, BCAR1 scaffold protein, Cas family member |
Background | CLIA Kits BCAR1 |
Status | RUO |
Note | The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request. This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein. |
Descripción
BCAR1, also known as the Breast Cancer Anti-Estrogen Resistance 1 protein, is an important protein involved in the development of resistance to anti-estrogen therapies, such as tamoxifen, used in the treatment of estrogen receptor-positive breast cancer. BCAR1 plays a crucial role in cell signaling pathways that regulate cell survival, proliferation, and resistance to apoptosis. It is often upregulated in breast cancer cells that become resistant to estrogen receptor-targeted therapies. The protein interacts with several other signaling molecules involved in the regulation of cell motility and survival, contributing to the metastatic potential of breast cancer cells. Understanding BCAR1’s role in therapy resistance has significant implications for developing alternative therapeutic strategies for patients with estrogen receptor-positive breast cancer who develop resistance to current treatments.
Related Products

Human BCAR1 (Breast Cancer Anti Estrogen Resistance 1) ELISA Kit
Ver Producto
BCAR1 antibody
Ver Producto